Science & Technology
Science and Technology
Science and Technology
Mon, December 1, 2008
CHICAGO--([ BUSINESS WIRE ])--CompuMed, Inc. (OTCBB:CMPD) ([ www.compumed.net ]) -- a medical informatics company serving the healthcare community with diagnostic software solutions – is teaming up with key OEM partners to showcase its OsteoGram® bone density imaging system this week at the 94th Annual Meeting of the Radiological Society of North America (RSNA) in Chicago.
The OsteoGram is on display with OEMs that have integrated the system with their own industry leading applications. OsteoGram OEMs at RSNA include CareStream Health (North Building – Hall B, Booth 8342), FujiFilm Medical Systems (South Building – Hall A, Booth 4039) and Swissray International (East Building – Hall D, Booth 1809).
The software-based OsteoGram system employs a patented imaging process to measure bone density from a standard hand x-ray. It is compatible with DICOM standards and has been shown in numerous clinical studies to provide effective and accurate bone density measurement for screening osteoporosis and assessing hip fracture risk. It has also demonstrated significant cost advantages over other available screening technologies.
"We are delighted to team up with some of the most renowned names in medical imaging to showcase the OsteoGram at RSNA," said CompuMed CEO Maurizio Vecchione.
The 2008 RSNA meeting is currently under way (November 30th– December 4th) at Chicago's McCormick Place. It is the world's largest medical conference and expo. This year's meeting is expected to be attended by more than 60,000 medical and scientific professionals from around the globe.
More information about the OsteoGram is available from CompuMed's authorized OEM and distribution partners or by visiting [ www.CompuMed.net ].
About CompuMed
CompuMed, Inc. (OTCBB:CMPD) develops and markets products and services that combine advanced imaging with medical informatics. Its focus is on analysis and remote monitoring for patients with cardiovascular and musculoskeletal diseases. The Company has specialized expertise and intellectual property in telemonitoring imaging and analysis designed to improve healthcare provider workflow and patient care while reducing costs. CompuMed's core products, the OsteoGram(R) and CardioGram(TM), are cleared by the FDA and reimbursable by Medicare. The OsteoGram is a non-invasive diagnostic system that has been proven by many clinical studies to provide effective and accurate bone density measurement for screening osteoporosis and assessing hip fracture risk. The OsteoGram has significant cost advantages over other technologies in the marketplace. The CardioGram system is one of the first telecommunication networks designed to remotely interpret electrocardiograms and is used by private practice, as well as government and corporate healthcare providers nationwide. The CardioGram delivers online electrocardiogram interpretations within minutes of receipt and has the additional capability of automatically providing an over-read (i.e., follow-up review) by a cardiologist. CompuMed is headquartered in Los Angeles and distributes its products worldwide both directly and through OEM partners. Visit CompuMed on-line at [ www.compumed.net ].
Statements contained in this press release that are not historical facts, such as statements about prospective earnings, savings, revenue, operations, revenue and earnings growth, results of contracts and other financial results, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including statements concerning the Company's plans, objectives, expectations and intentions are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements are subject to uncertainties and risks including, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, product and service demand and acceptance, changes in technology, ability to raise capital, the availability of appropriate acquisition candidates and/or business partnerships, economic conditions, the impact of competition and pricing, capacity and supply constraints or difficulties, government regulation and other risks identified in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-KSB and Quarterly Reports on Form 10-QSB. All such forward-looking statements are expressly qualified by these cautionary statements. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect events, conditions or circumstances on which any such statement is based after the date hereof, except as required by law.
